Listen Top Shows Blog

The first half of 2024 was strong as M&As and financings dominate

The first half of 2024 was strong as M&As and financings dominate

Update: 2024-07-26

Share

Description

Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be healthy for the biopharma market while the rest of the year is populated with question marks that include the U.S. presidential election and potential interest rate cuts.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Healing the health divide for women

Healing the health divide for women

2024-11-2220:54

Modifi gets creative on the rocky road to a multibillion-dollar buyout

Modifi gets creative on the rocky road to a multibillion-dollar buyout

2024-11-1323:56

A quantum leap into the future of drug development

A quantum leap into the future of drug development

2024-10-1717:32

Gene and cell therapies will propel innovation, says Astellas CCO

Gene and cell therapies will propel innovation, says Astellas CCO

2024-10-0727:17

Capricor’s CEO pursues a BLA and talks rare disease

Capricor’s CEO pursues a BLA and talks rare disease

2024-09-2715:50

The first half of 2024 was strong as M&As and financings dominate

The first half of 2024 was strong as M&As and financings dominate

2024-07-2618:01

The cost of delays in development and sales: It’s probably not what you think

The cost of delays in development and sales: It’s probably not what you think

2024-07-1716:44

ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

2024-05-3013:11

Fibrobiologics walks the unconventional financing path

Fibrobiologics walks the unconventional financing path

2024-05-1518:16

Back to fundamentals: The latest numbers point to better times

Back to fundamentals: The latest numbers point to better times

2024-05-0621:38

Mark McKenna storms back with Mirador and eyes the development landscape

Mark McKenna storms back with Mirador and eyes the development landscape

2024-04-2325:01

Biopharma execs seek to avoid pain points in AI integration

Biopharma execs seek to avoid pain points in AI integration

2024-04-1619:19

Six biopharma executives consider a tough 2023 and are hopeful for a better 2024

Six biopharma executives consider a tough 2023 and are hopeful for a better 2024

2023-12-1117:05

AI: driving drug development from effective to remarkable

AI: driving drug development from effective to remarkable

2023-09-0626:32

The struggle is real: The first half of 2023 was an uphill climb

The struggle is real: The first half of 2023 was an uphill climb

2023-08-1625:47

The biosimilars challenge to Humira revs up

The biosimilars challenge to Humira revs up

2023-07-2017:06

Preventing opioid overdoses with a smart patch

Preventing opioid overdoses with a smart patch

2023-06-0523:20

Better times ahead for the biopharma sector? Could be, the new numbers say

Better times ahead for the biopharma sector? Could be, the new numbers say

2023-04-2428:02

Radiopharmaceuticals: The next big disrupter?

Radiopharmaceuticals: The next big disrupter?

2023-04-0513:58

Cambrian carves out a new niche as it works to keep people from getting sick

Cambrian carves out a new niche as it works to keep people from getting sick

2023-02-2128:06

00:00

00:00

x

The first half of 2024 was strong as M&As and financings dominate

The first half of 2024 was strong as M&As and financings dominate